Delivery Order SPE2DB22D1106-SPE2DB25FFDH3
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $16,462.32 to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100 count) on May 30, 2025, with an ultimate completion date of June 23, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, will be performed at the contractor's facility in Conshohocken, Pennsylvania. Testopel is a testosterone replacement therapy product used in hormone treatment applications,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Testopel 75 mg pellets (100-count units) with a ceiling value of $4,115.58 and a firm fixed price structure. This is a non-set-aside competitive award with an ultimate completion date of October 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under...
- The Defense Logistics Agency awarded a $4,115.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Testopel 75 mg pellets (100-count units) on May 2, 2025, with an ultimate completion date of May 23, 2025. This non-competitive delivery order will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child contract under a larger...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at approximately $4,000 to Amerisourcebergen Drug Corporation for the supply of 100 units of Testopel 75 mg pellets. Performance will occur at Amerisourcebergen's facility in Conshohocken, Pennsylvania over a period of three weeks concluding in early September. As a major supplier of pharmaceuticals to the Department of Defense, this order for testosterone replacement therapy supports DLA's provision of medical...
- This is a $4,115.58 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TESTOPEL 75 MG PELLETS 100S, a pharmaceutical product, with a performance period ending on July 21, 2025. The contract is not set aside and was awarded on June 27, 2025. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,115.58, is for the delivery of TESTOPEL 75 MG PELLETS 100S medical supplies. The contract is a firm fixed-price delivery order that runs through May 5, 2025. It is not associated with any set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,978.09 contract is for the supply of TESTOPEL 75 MG PELLETS 100S, a medical product, with a period of performance through August 13, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This firm fixed price delivery order was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide 100 units of TESTOPEL 75 MG PELLETS. The order, valued at $3,978.09, is to be completed by January 26, 2024. Amerisourcebergen Drug Corp is a prime contractor that has received multiple awards from DLA Troop Support Medical to supply pharmaceuticals, medical supplies, and related distribution services in support of...
- This is a $3,978.09 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,565,289,653 units of TESTOPEL 75 MG PELLETS 100S. The award is not associated with a set-aside program. Amerisourcebergen, through its Corporate Office division, provides a wide range of pharmaceutical and medical products to various government agencies, including the military, under multiple indefinite...
- This is a $4,115.58 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TESTOPEL 75 MG PELLETS 100S, a pharmaceutical product, with a period of performance through July 1, 2025. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999.00...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFDH3Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Testopel 75 mg pellets (100-count units) with a ceiling value of $8.2K. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures and scheduled for completion by September 5, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion global pharmaceutical support vehicle valued through December 2026 that enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. Testopel is a testosterone replacement therapy product used in military and federal healthcare systems to address hormone deficiencies among service members and beneficiaries. AmerisourceBergen's role as a primary pharmaceutical distributor to the DLA positions the company as a critical vendor for federal medical procurement, with demonstrated capability to fulfill diverse pharmaceutical supply requirements across multiple therapeutic domains. The company's extensive federal contracting history and competitive awards reflect its established standing as a reliable provider of both brand-name and generic medications to defense and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.2k | 8/14/25 |